Abstract
Inflammatory breast cancer represents 2-5% of all malignant breast lesions. Its rapid progression, the rather short medical history of the disease is unique and seems to be very typical. The combined modality treatment of inflammatory breast cancer is a special challenge for the medical oncologists. Preoperative chemotherapy is of great importance. After getting fair remission, surgery and radiotherapy should be delivered. With combined modality therapy the 5-year overall survival is about 50%. Knowing more pharmaco-genomic details on the disease and delivering new medicaments the effectiveness of the treatment will be further enhanced.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / genetics
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / diagnosis
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology*
-
Breast Neoplasms / surgery
-
Breast Neoplasms / therapy*
-
CCN Intercellular Signaling Proteins
-
Chemotherapy, Adjuvant
-
Diagnosis, Differential
-
ErbB Receptors / analysis
-
ErbB Receptors / genetics
-
Female
-
Humans
-
Inflammation
-
Insulin-Like Growth Factor Binding Proteins / analysis
-
Insulin-Like Growth Factor Binding Proteins / genetics
-
Mastectomy / methods
-
Neoplasm Staging
-
Pharmacogenetics
-
Receptors, Estrogen / analysis
-
Receptors, Estrogen / genetics
-
Tumor Suppressor Protein p53 / analysis
-
Tumor Suppressor Protein p53 / genetics
-
rho GTP-Binding Proteins / analysis
-
rho GTP-Binding Proteins / genetics
-
rhoC GTP-Binding Protein
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
CCN Intercellular Signaling Proteins
-
CCN6 protein, human
-
Insulin-Like Growth Factor Binding Proteins
-
Receptors, Estrogen
-
Tumor Suppressor Protein p53
-
ErbB Receptors
-
RHOC protein, human
-
rho GTP-Binding Proteins
-
rhoC GTP-Binding Protein